Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Multidrug Resistance-1 C3435T Polymorphism and Carbamazepine Plasma Level in Indonesian Temporal Lobe Epilepsy Patients

Author(s): Astri Budikayanti, Herlyani Khosama, Fitri Octaviana, Donny H. Hamid, Melva Louisa, Teguh A.S. Ranakusuma and Rianto Setiabudy*

Volume 18, Issue 1, 2023

Published on: 20 May, 2022

Page: [62 - 68] Pages: 7

DOI: 10.2174/1574886317666220414130526

open access plus

Abstract

Background: Temporal lobe epilepsy (TLE) has the highest probability of becoming resistant. One of the causes was Polymorphism in multidrug resistant-1 (MDR1) C3435T. In Dr. Cipto Mangunkusumo Hospital, potential drug-resistant epilepsy prevalence was 84.51%; 66.6% of them used carbamazepine (CBZ) as antiseizure medication. This comparative cross-sectional study aimed to investigate MDR1 C3435T polymorphism and CBZ plasma level (plCBZ) in Indonesian TLE patients.

Methods: TLE patient was selected consecutively; divided into drug-responsive (DRV) and drugresistant (DRE) groups. Healthy subjects were included as a control for the gene polymorphism comparison. MDR1 was identified using the restriction fragment length polymorphism PCR technique; C allele at 159 and 57bp while T allele at 216bp. High-performance liquid chromatography was used to determine plCBZ.

Results: There were 86 subjects; 61 in the study group and 25 controls. The genotype distribution between them was 0.58 vs 0.42, x2=0.54, p=0.000. In the study group, CBZ within therapeutic doses (dCBZ) had outreached the therapeutic plCBZ and found similar in all genotypes. DRE criteria were found in 37 subjects. Distribution of C and T in DRV was 0.63 vs 0.37, x2=10.4; and DRE 0.55 vs 0.45 x2=6.17 (p=0.019). In Tukey’s multiple comparison post hoc test, CT in DRV had significantly lower dCBZ (330,36 ± 174,91 mg) and plCBZ (7.15 ± 2.64 mcg/mL) compared to all genotypes in DRE. Whereas mean dCBZ was around 800mg and plCBZ outreached the toxic level; TT was the highest.

Conclusion: The genotype MDR1 distribution was similar in the normal population and DRE. Therapeutic plCBZ was achieved using the low dose. CT genotype responds to lower dCBZ, while TT genotype outreached the highest toxic plCBZ.

Keywords: Indonesian, TLE, CBZ plasma level, MDR1 C3435T, carbamezepine, drug resistant epilepsy.

« Previous Next »
[1]
Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51(6): 1069-77.
[http://dx.doi.org/10.1111/j.1528-1167.2009.02397.x] [PMID: 19889013]
[2]
Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011; 365(10): 919-26.
[http://dx.doi.org/10.1056/NEJMra1004418] [PMID: 21899452]
[3]
Stępień KM, Tomaszewski M, Tomaszewska J, Czuczwar SJ. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep 2012; 64(5): 1011-9.
[http://dx.doi.org/10.1016/S1734-1140(12)70900-3] [PMID: 23238460]
[4]
Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 2012; 64(10): 930-42.
[http://dx.doi.org/10.1016/j.addr.2011.12.003] [PMID: 22197850]
[5]
Rambeck B, Jürgens UH, May TW, et al. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 2006; 47(4): 681-94.
[http://dx.doi.org/10.1111/j.1528-1167.2006.00504.x] [PMID: 16650134]
[6]
Kwan P, Sander JW. The natural history of epilepsy: An epidemiological view. J Neurol Neurosurg Psychiatry 2004; 75(10): 1376-81.
[http://dx.doi.org/10.1136/jnnp.2004.045690] [PMID: 15377680]
[7]
Mardjono M. Epilepsy: Few aspects in clinical problems with special interest in temporal lobe epilepsy. [dissertation] Jakarta: FKUI 1963.
[8]
Gunawan P, Octaviana F, Budikayanti A. Antiepileptic Drug Initiation in Relation with Seizure Free Period in Focal Epilepsy. 9th Asian & Oceanic Epilepsy Congress, March 22- 25, 2012. Singapore. Available from: www.epilepsysingapore2014.org
[9]
Wiratman W, Octaviana F, Budikayanti A. Efficacy of temporal lobe epilepsy in Cipto Mangunkusumo Hospital in Juni 2010 to Mei 2011. Neurona 2012; 29(3): 36-8.
[10]
Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348(15): 1442-8.
[http://dx.doi.org/10.1056/NEJMoa021986] [PMID: 12686700]
[11]
Ban J-J, Jung K-H, Chu K, et al. Profiles of multidrug resistance protein-1 in the peripheral blood mononuclear cells of patient with refractory epilepsy. PLoS One 2012; 7(5): 1-6.
[http://dx.doi.org/10.1371/journal.pone.0036985]
[12]
Sterjev Z, Trencevska GK, Cvetkovska E, et al. The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy. Neuropsychiatr Dis Treat 2012; 8: 191-6.
[PMID: 22570551]
[13]
Kwan P, Brodie MJ. Refractory epilepsy: A progressive, intractable but preventable condition? Seizure 2002; 11(2): 77-84.
[http://dx.doi.org/10.1053/seiz.2002.0593] [PMID: 11945093]
[14]
Lachos J, Zattoni M, Wieser H-G, et al. Characterization of the gene expression profile of human hippocampus in mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsy Res Treat 2011; 2011758407
[http://dx.doi.org/10.1155/2011/758407] [PMID: 22937234]
[15]
Kwan P, Li HM, Al-Jufairi E, et al. Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol Dis 2010; 39(2): 192-7.
[http://dx.doi.org/10.1016/j.nbd.2010.04.006] [PMID: 20403441]
[16]
Kwan P, Baum L, Wong V, et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav 2007; 11(1): 112-7.
[http://dx.doi.org/10.1016/j.yebeh.2007.04.013] [PMID: 17521963]
[17]
Shaheen U, Prasad DKV, Sharma V, et al. Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy. Epilepsy Res 2014; 108(2): 251-6.
[http://dx.doi.org/10.1016/j.eplepsyres.2013.11.009] [PMID: 24300029]
[18]
Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: A critical review and recommendations for future research. Pharmacogenomics J 2007; 7(3): 154-79.
[http://dx.doi.org/10.1038/sj.tpj.6500413] [PMID: 16969364]
[19]
Subenthiran S, Abdullah NR, Joseph JP, et al. Linkage disequilibrium between polymorphism of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex focal seizure on treatment with CBZ mono-therapy at the Kuala Lumpur Hospital. PLoS One 2013; 8(5): 1-6.
[http://dx.doi.org/10.1371/journal.pone.0064827] [PMID: 23717663]
[20]
Manna I, Gambardella A, Labate A, et al. Polymorphism of the multidrug resistance 1 gene MDR1/ABCB1 C3435T and response to antiepileptic drug treatment in temporal lobe epilepsy. Seizure 2015; 24: 124-6.
[http://dx.doi.org/10.1016/j.seizure.2014.09.010] [PMID: 25458099]
[21]
Lee CG, Chong SS, Lee EJD. Pharmacogenetics of the human MDR1 multidrug transporter. Curr Pharmacogenom 2004; 2: 1-11.
[http://dx.doi.org/10.2174/1570160043476097]
[22]
Demeule M, Régina A, Jodoin J, et al. Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 2002; 38(6): 339-48.
[http://dx.doi.org/10.1016/S1537-1891(02)00201-X] [PMID: 12529928]
[23]
Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001; 90(1): 21-34.
[http://dx.doi.org/10.1016/S0163-7258(01)00122-X] [PMID: 11448723]
[24]
Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32(11): 1959-72.
[http://dx.doi.org/10.1038/jcbfm.2012.126] [PMID: 22929442]
[25]
Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 2011; 8(1): 7.
[http://dx.doi.org/10.1186/2045-8118-8-7] [PMID: 21349155]
[26]
Zhang C, Zuo Z, Kwan P, Baum L. In vitro transport profile of CBZ, oxCBZ, eslicabazepine acetate, and their active metabolite by human P-glycoprotein. Epilepsia 2011; 52(10): 1894-904.
[http://dx.doi.org/10.1111/j.1528-1167.2011.03140.x] [PMID: 21692796]
[27]
Budikayanti A, Chaliana C, Louisa M, Setiabudy R. Development and validation of carbamazepine plasma concentrations measurement and its application on epilepsy patients. Int J Pharm Pharm Sci 2017; 9(9): 87-91.
[http://dx.doi.org/10.22159/ijpps.2017v9i9.19402]
[28]
Thurman DJ, Beghi E, Begley CE, et al. Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 2011; 52 (Suppl. 7): 2-26.
[http://dx.doi.org/10.1111/j.1528-1167.2011.03121.x] [PMID: 21899536]
[29]
Aswar A, Octaviana F, Budikayanti A, Prihartono J. Faktor-faktor yang memengaruhi epilepsi lobus temporal potensial resisten. Neurona 2015; 32(2): 117-23.
[30]
Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res 2009; 85(1): 31-45.
[http://dx.doi.org/10.1016/j.eplepsyres.2009.03.003] [PMID: 19369037]
[31]
Silva-Alves MS, Secolin R, Carvalho BS, et al. A prediction algorithm for drug response in patients with mesial temporal lobe epilepsy based on clinical and genetic information. PLoS One 2017; 12(1)e0169214
[http://dx.doi.org/10.1371/journal.pone.0169214] [PMID: 28052106]
[32]
Lu Q, Wu L, Jin L, Xu Q, Shen Y. Association analysis of polymorphism of MDR1 gene and refractory temporal lobe epilepsy in a Chinese population. Neurol Asia 2007; 12 (Suppl. 1): 94-5.
[33]
Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007; 75(2-3): 192-6.
[http://dx.doi.org/10.1016/j.eplepsyres.2007.06.003] [PMID: 17628429]
[34]
Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999; 34(2-3): 109-22.
[http://dx.doi.org/10.1016/S0920-1211(98)00106-5] [PMID: 10210025]
[35]
Nair DR. Management of drug-resistant epilepsy. Continuum (Minneap Minn) 2016; 22(1): 157-72.
[http://dx.doi.org/10.1212/CON.0000000000000297] [PMID: 26844735]
[36]
Ibrahim H, Rahman AFA. Pharmacokinetic parameters of valproic acid and carbamazepine from routinely collected data: Influence of patient characteristics. MJPS 2008; 6(1): 33-42.
[37]
Krasniqi S, Neziri B, Islami H, Bauer S. Carbamazepine and lamotrigine plasma concentrations in epileptic patients during optimising therapy. Med Arh 2010; 64(2): 80-3.
[PMID: 20514770]
[38]
Budikayanti A, Khosama H, Chaliana C, et al. Carbamazepine plasma level in temporal lobe epilepsy. Neurona 2017; 34(3): 125-31.
[39]
Barcs G, Halász P. Effectiveness and tolerance of clobazam in temporal lobe epilepsy. Acta Neurol Scand 1996; 93(2-3): 88-93.
[http://dx.doi.org/10.1111/j.1600-0404.1996.tb00180.x] [PMID: 8741124]
[40]
Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K. Use of clobazam for the treatment of refractory complex partial seizures. Seizure 2003; 12(5): 282-6.
[http://dx.doi.org/10.1016/S1059-1311(02)00287-X] [PMID: 12810340]
[41]
Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav 2011; 21(1): 27-30.
[http://dx.doi.org/10.1016/j.yebeh.2011.02.015] [PMID: 21493161]

Rights & Permissions Print Cite
Article Metrics
7
© 2025 Bentham Science Publishers | Privacy Policy